Exhibit 99.2
Management’s Discussion and Analysis
For the Three Months Ended
June 30, 2022
DATE OF REPORT: August 12, 2022
MANAGEMENT’S DISCUSSION AND ANALYSIS
The following management’s discussion and analysis (“MD&A”)
has been prepared as at August 12, 2022 for the three months ended June 30, 2022 and should be read in conjunction with the unaudited
interim condensed consolidated financial statements of Medicenna Therapeutics Corp. for the three months ended June 30, 2022 and 2021,
and the annual consolidated financial statements and accompanying notes for the years ended March 31, 2022 and 2021 (the “Annual
Financial Statements”), which have been prepared in accordance with International Financial Reporting Standards (“IFRS”)
as issued by the International Accounting Standards Board (“IASB”). Our IFRS accounting policies are set out in note 2 of
the Annual Financial Statements and all dollar amounts are expressed in Canadian dollars unless otherwise noted.
All references in this MD&A to “the Company”, “Medicenna”,
“we”, “us”, or “our” and similar expressions refer to Medicenna Therapeutics Corp. and the subsidiaries
through which it conducts its business, unless otherwise indicated.
FORWARD-LOOKING STATEMENTS
This MD&A contains forward-looking statements within the meaning
of applicable securities laws. Forward-looking statements are neither historical facts nor assurances of future performance. Instead,
they are based on current beliefs, expectations or assumptions regarding the future of the business, future plans and strategies, operational
results and other future conditions of the Company. These statements involve known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any
future results, performance or achievements expressed or implied by such forward-looking statements. All statements contained herein other
than statements of historical fact regarding the prospects of the Company’s industry or its prospects, plans, financial position
or business strategy may constitute forward-looking statements and can generally be identified by the use of forward-looking words, such
as “plan”, “expect”, “is expected”, “budget”, “scheduled”, “estimate”,
“forecast”, “contemplate”, “intend”, “anticipate”, or “believe” or variations
(including negative variations) of such words and phrases, or statements that certain actions, events or results “may”, “could”,
“would”, “might”, “shall” or “will” be taken, occur or be achieved and similar expressions
are generally intended to identify forward-looking statements.
By their very nature, forward-looking statements involve inherent risks and uncertainties,
both general and specific, and risks exist that predictions, forecasts, projections and other forward-looking statements will not be
achieved. The Company cautions readers not to place undue reliance on these statements as a number of important factors could cause
the actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions
expressed in such forward-looking statements. Risks, uncertainties and other factors which may cause the actual results, performance
or achievements of the Company, as applicable, to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking information and statements include, but are not limited to, the risks described under
the heading “Risks and Uncertainties” in this MD&A, the Company’s annual information form for the fiscal year
ended March 31, 2022 (the “Annual Information Form”) and the Company’s annual report on Form 20-F for the fiscal
year ended March 31, 2022 (the “Annual Report on Form 20-F”) filed with the U.S. Securities and Exchange Commission.
Forward-looking statements in this MD&A include, but are not limited
to:
| · | the lack of product revenue and inability to continue operations and research and development without
sufficient funding; |
| · | the Company’s requirements for, and our ability to obtain, future funding on favourable terms or
at all; |
| · | the Company’s history of losses and expectations of future losses; |
| · | the Company’s inability to complete development of or the inability to commercialize the Company’s
product candidates, which are in the early stages of development; |
| · | the expense, length, and uncertainty of clinical drug development programs; |
| · | the inability to achieve publicly announced milestones according to schedule, or at all; |
| · | the risk that competitors may develop and market products that are more effective that the Company’s
product candidates or that the products developed by competitors may render the Company’s product candidates obsolete or uncompetitive; |
| · | the Company’s inability to secure a partnership for MDNA55; |
| · | the costs and uncertainty associated with extensive government regulation; |
| · | the obtaining of regulatory approvals, including delays or negative outcomes from the regulatory approval
process; |
| · | the potential negative results from clinical trials or studies, or adverse safety events involving the
targets of the Company’s products, including in the demonstration of efficacy and safety; |
| · | the pharmacokinetic (“PK”) and pharmacodynamic (“PD”) properties of MDNA11 and
MDNA19; |
| · | the tumour response data from our clinical trials; |
| · | the risk of product liability claims; |
| · | the Company’s inability to enroll subjects in clinical trials or complete clinical trials on a timely
basis |
| · | the failure of our product candidates to receive the marketing approval or market acceptance necessary
for commercial success; |
| · | the potential for environmental exposure to hazardous or radioactive materials that are used in the Company’s
discovery and development process; |
| · | the disruption in the availability of key components for ongoing clinical studies that could delay clinical
studies, product testing, and regulatory approval of the Company’s product candidates |
| · | the Company’s reliance on third parties for the planning, conduct, and monitoring of preclinical
and clinical trials and for the manufacture of drug product; |
| · | the Company’s reliance on contract manufacturers over whom the Company has limited control; |
| · | the loss of license rights due to breach of license agreements; |
| · | the conditions and restrictions of the Cancer Prevention Research Institute of Texas (“CPRIT”)
grant; |
| · | the potential uses of proceeds generated under Company’s offerings; |
| · | the ability to protect the Company’s intellectual property and proprietary technology; |
| · | the ability for the Company to obtain patent’s term extensions; |
| · | the potential involvement in intellectual property litigation; |
| · | the risk that third-parties to whom we rely for product development may not adequately protect the Company’s
trade secrets; |
| · | the risk of product liability claims; |
| · | the limitations surrounding intellectual property rights |
| · | the volatility in the price of our Common Shares |
| · | the dilution of investor’s voting power and reductions in earnings per share owing to future issuances
of equity or the conversion of securities into Common Shares; |
| · | the fact that future profits will likely be used for the continued growth of the Company’s business
and not for the payment of dividends |
| · | the Company’s treatment as a passive foreign investment company and potential adverse U.S. federal
income tax consequences associated with such treatment; |
| · | the difficulty United States investors may face in bringing actions against the Company for violations
of U.S. federal or state securities laws and challenges in enforcing the judgments of U.S. courts against the Company and its directors
and executive officers; |
| · | the Company’s status as a foreign private issuer under applicable U.S. securities laws; |
| · | the ability of the Company’s significant shareholders to assert a material influence over the Company’s
operations and governance; |
| · | the adverse impact of factors outside our control, such as global health pandemics, natural disasters,
geopolitical conflict and macroeconomic challenges; |
| · | the Company’s ability to successfully manage its growth; |
| · | the failure of any acquired business, product, service, or alliance to yield expected benefits |
| · | the Company’s dependence upon certain key personnel, the loss of whom could adversely affect our
ability to achieve our business objectives; |
| · | changes in government regulations that could impact our business and operations; |
| · | failure to comply with the U.S. Foreign Corrupt Practices Act, the Canadian Corruption of Foreign Public
Officials Act and other global corruption and anti-bribery laws; |
| · | a failure to comply with healthcare laws; |
| · | foreign currency exchange risks relating to the relative value of the United States dollar; |
| · | the failure of our disclosure controls and procedures to detect all errors or prevent all incidences of
fraud; |
| · | the failure to maintain an effective system of internal controls; |
| · | the vulnerability of the computer and information systems of the Company, its consultants and contractors,
and third-parties on which the Company relies, to security breaches or failure; and |
| · | the pursuit of opportunities for further research and development or additional business opportunities. |
Although the Company has attempted to identify important factors that
could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other
factors that cause actions, events or results to differ from those anticipated, estimated or intended.
The forward-looking information in this MD&A does not include a full assessment
or reflection of the unprecedented impacts of the COVID-19 pandemic and the efforts to mitigate it and the ongoing and developing indirect
global and regional economic impacts. The Company continues to experience uncertainty related to the on-going COVID-19 pandemic. The spread
of COVID-19 and global measures to contain it and its variants, have had, and are anticipated to continue to have an impact on the Company,
however it is challenging to quantify the potential future magnitude of such impact at this time. The Company is regularly assessing the
situation and remains in contact with its partners, clinical sites and investigators, contract research organizations, contract development
and manufacturing organizations and suppliers to assess any impacts and risks. The Company believes that ongoing COVID-19 restrictions
could impact the planned clinical development timelines of the MDNA11 Phase 1/2 clinical trial including patient recruitment although
the Company is not aware of any delays at this time.
All forward-looking statements reflect the Company’s beliefs and assumptions
based on information available at the time the assumption was made.
Although the forward-looking statements contained in this MD&A are
based upon what the Company’s management believes to be reasonable assumptions, the Company cannot assure readers that actual results
will be consistent with these forward-looking statements.
Any forward-looking statements represent the Company’s estimates
only as of the date of this MD&A and should not be relied upon as representing the Company’s estimates as of any subsequent
date. The Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after
the date on which such statement is made or to reflect the occurrence of unanticipated events, except as may be required by securities
laws.
COMPANY OVERVIEW
The Company's principal business activity is the development and commercialization
of Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Medicenna has four wholly
owned subsidiaries, Medicenna Therapeutics Inc. (British Columbia), Medicenna Biopharma Inc. (Delaware), Medicenna Biopharma Inc. (British
Columbia) and Medicenna Australia PTY Ltd (Australia) (“MAL”). On November 13, 2017, Medicenna continued under the Canada
Business Corporations Act. On August 24, 2020, Medicenna began trading on the Nasdaq Capital Market (“Nasdaq”) under
the symbol “MDNA.
Medicenna is an immunotherapy company developing novel, highly selective
versions of interleukin-2 (“IL-2”), interleukin-4 (“IL-4”) and interleukin-13 (“IL-13”) tunable cytokines,
called “Superkines”. These Superkines can be developed either on their own as short or long-acting therapeutics or fused with
cell killing proteins in order to generate Empowered Superkines that precisely deliver potent payloads to cancer cells without harming
adjacent healthy cells. Superkines can also be fused with a large variety of proteins, antibodies and even other Superkines in order to
incorporate two synergistic therapeutic activities into one molecule, creating novel Bi-Functional SuperKine ImmunoTherapies
referred to by Medicenna as BiSKITsTM. Medicenna’s mission is to become the leader in the development and commercialization
of Superkines, Empowered Superkines and BiSKITsä for the treatment of a broad range of cancers
and other diseases. The Company seeks to achieve its goals by drawing on its expertise, and that of world-class collaborators and advisors,
in order to develop Revolutionary Medicines using Evolutionary Superkines. Compared to naturally occurring cytokines – that bind
to multiple receptors on many cell types – Superkines are engineered with unique selectivity toward specific receptor subtypes and
defined target cell subsets in order to precisely activate or inhibit relevant signalling pathways or immune cells in order to improve
therapeutic efficacy and safety.
Medicenna has built a diverse platform, each comprised
of a pipeline of Superkine candidates in-licensed from Leland Stanford Junior University (“Stanford”). This includes the MDNA109
platform that consists of IL-2 agonists, IL-2 antagonists and partial agonists of IL-2. Additional assets from Stanford also include several
super-agonists of IL-4 and IL-13 and dual IL-4/IL-13 antagonists. In addition, Medicenna has also independently developed therapeutic
agents based on its Empowered Superkine and BiSKITsä platforms.
The most advanced of these programs is the MDNA109 platform which is
a genetically engineered IL-2 Superkine designed to specifically bind to CD122 (IL-2Rβ) with high affinity. To further enhance its
selectivity, 2 additional mutations (FEAA) were incorporated in MDNA109 to abolish binding to CD25. To improve the PK properties of the
highly selective version of MDNA109 (MDNA109FEAA), it was genetically fused to protein scaffolds such as the Fc domain of IgG1 (MDNA19)
or human albumin (MDNA11) effectively increasing the size of the Superkine and improving its half-life in order to avoid frequent daily
dosing required for Proleukinâ.
We believe that, unlike Proleukinâ,
both MDNA11 and MDNA19, have superior PK properties, lack CD25 binding to improve safety and reduce immune suppression, potently stimulate
effector T cells, reverse natural killer (“NK”) cell exhaustion and act with exceptional synergy when combined with checkpoint
inhibitors.
Although MDNA19 was initially identified as the Company’s lead
IL-2 candidate, a pilot non-human primate (“NHP”) study comparing MDNA11 with MDNA19 demonstrated that the former had better
PK and pharmacodynamic (“PD”) features. Medicenna is therefore advancing the clinical development of MDNA11 as it is a more
promising molecule and has been selected as the lead IL-2 Superkine candidate. Medicenna initiated the Phase 1/2 ABILITY Study (A Beta-only
IL-2 ImmunoTherapY Study) with MDNA11 (the “ABILITY Study”) in the third calendar quarter of 2021. MDNA19
remains relevant for Medicenna as it provides unique design features in the development of our BiSKITsTM platform. Our BiSKITsTM
platform allows us to develop designer Superkines by fusing them to other proteins, antibodies, cytokines or other Superkines in order
to incorporate two distinct but synergistic functions into one molecule: a BiSKITTM.
Complementing our Superkine platform is MDNA55, Medicenna’s Empowered
Superkine, for the treatment of recurrent glioblastoma (“rGBM”), the most common and uniformly fatal form of brain cancer.
MDNA55 is a fusion of a circularly permuted version of IL-4, fused to a potent fragment of the bacterial toxin, Pseudomonas exotoxin (“PE”),
and is designed to preferentially target tumor cells that over-express the interleukin 4 receptor (“IL-4R”). MDNA55 has been
studied in 5 clinical trials in 132 patients, including 112 patients with rGBM, the results of which support our belief that it has superior
efficacy when compared to the current standard of care (“SOC”). MDNA55 has secured Orphan Drug Status from the United States
Food and Drug Administration (“FDA”) and the European Medicines Agency (“EMA”) as well as Fast Track Designation
from the FDA for the treatment of rGBM and other types of high grade glioma. We continue to pursue a strategic partnership to facilitate
MDNA55’s further development and commercialization.
ACHIEVEMENTS & HIGHLIGHTS
The following are the achievements and highlights for
the three months ending June 30, 2022 through to the date hereof:
| · | On April 8, 2022, Medicenna announced new preclinical data on its
long-acting dual IL-4/IL-13 super antagonist, Fc-MDNA413, during a poster session at the American Association for Cancer Research (AACR)
Annual Meeting (“AACR Annual Meeting”). |
| · | On April 8, 2022, Medicenna also announced new preclinical data
highlighting the potent anti-tumor efficacy of the next-generation BiSKIT, anti-PD1-MDNA109FEAA, an anti-PD1antibody fused to an IL-2
Superkine, during a poster session at the AACR Annual Meeting. |
| · | On May 2, 2022, Medicenna announced new clinical data from the Phase
1/2 ABILITY Study. |
| · | On May 11, 2022 , Medicenna announced that clinical data from the
Phase 1/2 ABILITY Study, were featured in a poster presentation at the 9th Annual Frontiers in Cancer Immunotherapy Meeting
organized by the New York Academy of Sciences (“NYAS”).. |
| · | On June 9, 2022, Medicenna announced that the U.S.
Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,352,402 titled, “Interleukin-4 Receptor-Binding Fusion Proteins
And Uses Thereof.” The patent provides intellectual property (IP) protection for composition and methods of treating degenerative
diseases via administration of a fusion protein comprising an IL-4 or IL-13 Superkine and an anti-apoptotic Bcl-2 family polypeptide.
The patent’s term extends into at least 2038 without accounting for any potential extensions. |
| · | On July 27, 2022, Medicenna announced new clinical data on safety, pharmacodynamics and anti-tumor activity
from the Phase 1/2 ABILITY study of MDNA11. The data provide preliminary evidence of MDNA11’s single agent anti-cancer activity
in patients with advanced solid tumors who have been unresponsive to other treatments, were featured in an oral presentation at the Cytokine
Based Drug Development Summit. |
| · | On August 11, 2022 the Company announced the closing of a marketed underwritten public offering of 13,333,334 units
(the “Unit”) of the Company in the Canada and in the United States at a price to the public of US$1.50 per Unit (the “Offering”).
The gross proceeds to the Company from the Offering were US$20 million, before deducting underwriting discounts and commission and other
expenses. Each Unit is comprised of one common share and one common share purchase warrant (a “Warrant”). Each Warrant entitles
the holder thereof to purchase one common share at a price of US$1.85 per common share, subject to adjustment in certain events, during
a period of 60 months following August 11, 2022. |
FINANCING UPDATE
Subsequent event
On August 11, 2022, subsequent to the quarter end, Medicenna completed the
Offering and issued 13,333,334 Units for aggregate gross proceeds of US$20 million. Each Unit is comprised of one common share and one
Warrant.
Three months ended June 30,
2022
On December 30, 2020, the Company entered into a sales agreement with SVB Leerink
LLC (“SVB Leerink”) acting as sales agent (the “ATM Agreement”), pursuant to which the Company may, from time
to time sell, through at-the-market (“ATM”) offering on the Nasdaq such number of common shares as would have an aggregate
offering price of up to US$25.0 million (the “ATM Facility”). The Company plans to use the net proceeds of the ATM offering
for general corporate purposes including, but not limited to working capital expenditures, research and development expenditures, and
clinical trial expenditures. During the three months ended June 30, 2022, the Company issued 656,656 common shares (June 30, 2021 –
nil) for gross proceeds of US$0.8 million (June 30, 2021 - $nil) at an average price of US$1.20. The Company received, net of commissions,
US$0.7 million (June 30, 2021 - $nil). In total, the Company incurred share issuance costs (including commissions) of US$0.1 million (June
30, 2021 - $nil).
During the three months ended June 30, 2022, no warrants were exercised.
Three months ended June 30, 2021
During the three months ended June 30, 2021, 169,236 warrants were exercised
for proceeds of $0.3 million, the details of which are described below:
| | Number of
Warrants | | |
| Exercise
Price | | |
| Proceeds | | |
Expiry Date |
| | | | |
| $ | | |
| $ | | |
|
| | 50,000 | | |
| 1.20 | | |
| 60,000 | | |
December 21, 2023 |
| | 119,236 | | |
| 1.75 | | |
| 208,663 | | |
October 17, 2022 |
| | 169,236 | | |
| | | |
| 268,663 | | |
|
RESEARCH & DEVELOPMENT UPDATE
Superkine Platform
MDNA11
On September 14, 2021, we announced that we had dosed the first patient
in a Phase 1/2 clinical study of MDNA11. Medicenna’s Phase 1/2 ABILITY Study is designed to assess the safety, PK, PD, and anti-tumor
activity of various doses of MDNA11 administered intravenously every 2 weeks, in patients with advanced solid tumors. The basket, dose
finding study includes a dose escalation phase followed by a dose expansion phase with both an MDNA11 monotherapy arm as well as a combination
arm designed to evaluate MDNA11 with a checkpoint inhibitor. The study will include patients with melanoma and renal cell carcinoma where
Proleukinâ is known to have clinical activity, as well as cluster of other tumor types
in order to explore the pan-tumor potential of MDNA11. The study also permits alternative dosing schedules, as well as options for intra-patient
dose escalation. The ABILITY study is currently enrolling patients at clinical sites in Australia, Canada and the United States.
On
May 2, 2022, Medicenna announced new clinical data from the third cohort of the Phase 1/2 ABILITY Study of MDNA11. This data was subsequently
updated in July as described below.
On May 11, 2022
, Medicenna presented additional clinical data from the Phase 1/2 ABILITY Study during a poster presentation at the 9th Annual Frontiers
in Cancer Immunotherapy Meeting, organized by the NYAS. This data was subsequently updated in July
as described below.
On July 27, 2022, Medicenna announced new clinical
data on safety, PK, PD and anti-tumor activity from the Phase 1/2 ABILITY Study of MDNA11 which were presented at the Cytokine Based Drug
Development Summit, held in Boston.
In the dose escalation portion of the ABILITY Study, MDNA11 is administered
intravenously, as a monotherapy, once every two weeks to patients with advanced solid tumors. The trial’s first two cohorts evaluated
MDNA11 doses ≤ 10 µg/kg. The trial’s third cohort was administered a dose of 30 µg/kg. Patients in the fourth and
fifth dose escalation cohorts receive two 30 µg/kg “priming” doses of MDNA11 before stepping up to receive fixed doses
of 60 and 90 µg/kg, respectively.
Key data from patients enrolled in the trial’s four initial dose escalation
cohorts include:
Demographics:
| - | Patients enrolled in the study to date (N=14) have failed up to four lines of prior systemic therapy. |
| - | 11 of 14 patients have relapsed, were not tolerant to or did not respond to at least one prior immunotherapy
with a checkpoint inhibitor. |
| - | To date, 10 of the 14 enrolled patients, including two of six patients in Cohort 4, have received at least
one post-baseline scan and are evaluable for response to the investigational treatment. |
Safety:
| - | MDNA11 treatment in Cohort 4 (comprised of two step-up doses of 30 µg/kg followed by fixed doses
of 60 µg/kg every 2 weeks) was not associated with any dose-limiting toxicities. |
| - | The Safety Review Committee approved dose escalation for Cohort 5 to the 90 µg/kg dose every 2 weeks
following two priming doses at 30 µg/kg. |
| - | Significant increases in eosinophil count from baseline were not observed with MDNA11 treatment. Extremely
high eosinophil count is associated with vascular leak syndrome which is a known side effect of high-dose recombinant human IL-2 (Proleukin®). |
Pharmacokinetics:
| - | The pharmacokinetic data from the first 3 cohorts demonstrated similar trends following each of 3 repeat
doses which suggests lack of immunogenicity or insignificant levels of anti-drug-antibodies. |
| - | Dose dependent increase in the Cmax and Area Under the Curve (“AUC”) were also
observed. |
Pharmacodynamics:
| - | In addition to dose dependent increases in lymphocyte counts and lymphocyte kinetics, MDNA11 preferentially
expanded anti-cancer NK and CD8+ T cells without stimulating proliferation of pro-tumor Treg cells. |
| - | MDNA11 treatment potently activated anti-cancer CD8+ T cells as shown by increases in both CD25+ and ICOS+
CD8+ T cells. |
| - | Unlike IL-2, MDNA11 has not induced increases in ICOS+ Treg cells. ICOS+ Treg cells are highly immunosuppressive
and associated with lack of response to high dose IL-2 immunotherapy. |
Anti-tumor Activity:
| - | Of the ten (10) evaluable patients with at least one on-treatment imaging scan, four (4) patients have
achieved tumor control (defined as stable disease, partial response, or complete response as per RECIST 1.1) during the monotherapy dose-escalation
portion of the MDNA11 ABILITY Study as follows: |
| 1. | Metastatic Leiomyosarcoma Stage IV (Dose Level 2 @ 10 µg/kg); stable disease |
| 2. | Metastatic Melanoma Grade 4C (initially enrolled at Dose Level 2 @ 10 µg/kg Q2W with subsequent
intra-patient dose escalations to Dose Level 3 @30 µg/kg and Dose Level 4 @60 µg/kg), stable disease |
| 3. | Metastatic Sarcoma Stage IV (Dose Level 3 @ 30 µg/kg), stable disease |
| 4. | Pancreatic Ductal Adenocarcinoma (PDAC) Stage IV (Dose Level 4 @ 60 µg/kg following 2 divided doses
of 30 µg/kg), unconfirmed partial response. |
As per RECIST 1.1 guidelines, the patient with PDAC in Dose Level 4 had stable
disease at the 12-week scan and a further reduction in tumor size at week 16 (³ 30% relative
to baseline scan) consistent with an unconfirmed partial response. The unconfirmed partial response is preliminary and subject to
further review. As per protocol and RECIST 1.1, a second scan at ³ 28 days after the most
recent scan is required to confirm a partial response in this patient. The preliminary data from this scan are subject to change if tumor
reduction of at least ³ 30% relative to baseline scan is not maintained or a new tumor lesion
is identified or the patient has clinical progression and is unable to continue the study or is unable to receive a confirmatory scan.
As a result, the preliminary data from this scan are subject to change and not predictive of the final results. There can be no assurance
that, upon completion of the confirmatory scan, that the patient will have a partial response. See “Risks and Uncertainties”
below.
Medicenna anticipates completing the following upcoming milestones
related to the MDNA11 ABILITY Study:
| 1) | Fourth Dose Cohort Initial Anti-Tumor Activity Data - September 2022; |
| 2) | Fifth Dose Cohort Initial Anti-Tumor Activity Data - Q4-2022; |
| 3) | Single Agent Expansion Anti-Tumor Activity Data - Mid-2023; |
| 4) | Combination Study Top-Line Anti-Tumor Activity Data - 2H-2023. |
BiSKITsTM (Bi-functional SuperKine ImmunoTherapies)
Platform
Our BiSKITsTM
platform allows us to develop designer Superkines by fusing them to other proteins, antibodies, cytokines or other Superkines to combine
two distinct but synergistic functions into one molecule: a BiSKITTM.
On April 8, 2022, we announced new preclinical data highlighting
the potent anti-tumor efficacy of the next-generation BiSKIT, anti-PD1-MDNA109FEAA, in an electronic poster at the AACR Annual Meeting.
BiSKITs can target cancers where other immunotherapies have failed to be effective. One example of this is MDNA223, an IL-2 Superkine
fused to a checkpoint inhibitor (anti-PD1). MDNA223 is a BiSKIT designed to activate cancer killing immune cells via the IL-2 receptor
while simultaneously preventing their exhaustion through the validated method of blocking PD-1 signaling. Combining these two functions
into a single molecule allows us to simultaneously engage both of these important targets on the same immune cells (also known as cis-binding).
Data from murine tumor models using a mouse version of MDNA223
(i.e MDNA223m) showed dose-dependent and statistically significant improvements in efficacy compared to co-administration of the anti-PD-1
antibody and IL-2 super-agonist (MDNA19) at equivalent molar doses, demonstrating the advantage of exploiting the BiSKIT’s cis-binding
potential.
Medicenna’s IL-4 and IL-13 Superkines are engineered versions
of wild type cytokines which possess enhanced affinity and selectivity for either the Type 1 or Type 2 IL4 receptors or dedicated IL13
receptors such as IL13Ra2. This selectivity is achieved through mutations of the IL-4 or IL-13
proteins to enhance affinity for binding to specific IL4R or IL13R subunits. Additional mutations have also been engineered to modulate
their bioactivity, resulting in Superkines with enhanced signaling (super-agonists) or the ability to block signaling (super-antagonists).
On
April 8, 2022, Medicenna announced new preclinical data on its long-acting IL-13 super-antagonist, Fc-MDNA413, in an electronic poster
at the AACR Annual Meeting. Fc-MDNA413 is derived from Medicenna’s Superkine platform and comprises of an IL-13 super-antagonist
(MDNA413) fused to the Fc domain for half-life extension.
Medicenna is currently screening and optimizing
a variety of IL-2/IL-4/IL-13 Superkines as part of our BiSKITsTM
platform with the goal of having a BiSKIT candidate IND ready by the end of calendar 2023.
MDNA55
MDNA55 has been studied in 5 clinical trials in 132 patients, including 112
patients with rGBM, suggesting potentially superior efficacy when compared to the current SOC. The Company has secured Orphan Drug Status
from the FDA and the EMA as well as Fast Track Designation from the FDA.
A Phase 2b clinical trial with MDNA55 was completed in a multi-center,
open-label, single-arm study in patients with first or second recurrence or progression of GBM after surgery or radiotherapy ±
adjuvant therapy or other experimental therapies. Subsequently, a separate blinded study that collected rGBM survival and prognostic data
from 81 patients, that had contemporaneously received treatment at major clinical centres using current SOC, were used to establish a
matched External Control Arm (“ECA”). The blinded survival data from the matched ECA (established by matching with the MDNA55
treated population based on 11 different prognostic factors using propensity scoring methods) were then used as a control arm versus survival
data from the Phase 2b MDNA55 trial.
On September 29, 2020, Medicenna had an End of Phase 2 (EOP2) meeting
with the FDA to discuss future development and commercialization of MDNA55, if approved for rGBM. On October 15, 2020, we announced that
the FDA agreed that we could conduct an innovative open-label hybrid Phase 3 trial that allows use of a substantial number of patients
(two-thirds) from a matched ECA to support marketing authorization of MDNA55 for rGBM. Medicenna is pursuing strategic partnerships to
assist with additional clinical development of MDNA55, as well as preparing the program for commercialization and its subsequent launch
in various countries where marketing authorization has been granted.
SELECTED FINANCIAL INFORMATION
All tabular amounts below are presented in thousands of Canadian dollars, except for per
share amounts.
| | |
|
Three months ended
June 30, 2022 |
| |
|
Three months ended
June 30, 2021 |
|
| | |
|
$ |
| |
|
$ |
|
| General and administration | |
| 1,919 | | |
| 1,867 | |
| Research and development | |
| 2,411 | | |
| 4,349 | |
| Net loss | |
| (4,155 | ) | |
| (6,386 | ) |
| Basic and diluted loss per share | |
| (0.07 | ) | |
| (0.12 | ) |
| Total assets | |
| 20,140 | | |
| 37,336 | |
| Total liabilities | |
| 2,147 | | |
| 4,958 | |
We have not earned revenue in any of the previous fiscal years, other
than income from interest earned on our cash and cash equivalents and marketable securities.
For the three months ended June 30, 2022, we reported a net loss of
$4.2 million ($0.07 loss per share), compared to a net loss of $6.4 million ($0.12 loss per share) for the three months ended June 30,
2021. The decrease in net loss for the period ended June 30, 2022, compared with the period ended June 30, 2021, was primarily a result
of decreased research and development expenditures related to the MDNA11 program, where GMP manufacturing and IND-enabling studies were
being conducted in the prior year quarter. There was a reimbursement of $1.8 million under the grant from CPRIT in the period ended June
30, 2021 which offset R&D expenditures and no reimbursement in the current year period.
Cash utilized in operating activities for the three months ended June
30, 2022 was $2.3 million, compared to cash utilized in operating activities for the three months ended June 30, 2021 of $4.6 million.
The decrease in cash utilized in the current year is primarily the result of decreased research and development expenses, and refundable
tax credits of $0.7 million received in the current year quarter.
RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDING JUNE 30, 2022
Research and Development (“R&D”) Expenses
| | |
|
Three months
ended
June 30, 2022 |
| |
|
Three months
ended
June 30, 2021 |
|
| | |
| $ | | |
| $ | |
| Research and Development Expenses | |
| | | |
| | |
| Chemistry, manufacturing, and controls | |
| 495 | | |
| 3,392 | |
| Regulatory | |
| 28 | | |
| 214 | |
| Discovery and pre-clinical | |
| 470 | | |
| 688 | |
| Clinical | |
| 630 | | |
| 650 | |
| Salaries and benefits | |
| 514 | | |
| 654 | |
| Licensing, patent, legal fees and royalties | |
| 161 | | |
| 222 | |
| Stock based compensation | |
| 111 | | |
| 193 | |
| CPRIT grant claimed in eligible expenses (Note 6) | |
| - | | |
| (1,753 | ) |
| Other research and development expenses | |
| 2 | | |
| 89 | |
| | |
| 2,411 | | |
| 4,349 | |
R&D expenses of $2.4 million were incurred during the three months
ended June 30, 2022, compared with $4.3 million incurred in the three months ended June 30, 2021.
The decrease in R&D expenses during the current year period is primarily
attributable to:
| · | One-time higher chemistry, manufacturing and controls costs (“CMC”), associated with the first
scale-up GLP and GMP manufacturing of MDNA11 required to supply adequate drug product for IND-enabling studies and the ABILITY Study,
completed in the prior year period. |
| · | Decrease in regulatory costs due to the preparation of regulatory filings necessary to initiate the MDNA11
ABILITY study incurred in the prior year period. |
| · | Lower salary and benefits costs due to headcount reductions in the current year period. |
| · | Decrease in licensing costs, due to market research studies, completed in the prior year period. |
The above decreases were partially offset by the reimbursement of previously
incurred expenses with respect to the CPRIT grant of $1.8 million in the three months ended June 30, 2021, compared with $nil in
the three months ended June 30, 2022.
General and Administrative (“G&A”) Expenses
| | |
|
Three months ended
June 30, 2022 |
| |
|
Three months ended
June 30, 2021 |
|
| | |
| $ | | |
| $ | |
| General and Administration Expenses | |
| | | |
| | |
| Depreciation expense | |
| 1 | | |
| 10 | |
| Stock based compensation | |
| 295 | | |
| 161 | |
| Facilities and operations | |
| 124 | | |
| 80 | |
| Public company expenses | |
| 1,277 | | |
| 1,422 | |
| Salaries and benefits | |
| 222 | | |
| 194 | |
| | |
| 1,919 | | |
| 1,867 | |
G&A expenses of $1.9 million were incurred during the three months
ended June 30, 2022, compared with $1.9 million during the three months period ended June 30, 2021.
G&A expenses have remained consistent quarter over quarter. The increase
in stock based compensation in the current year period is due to timing and value of option grants, which was offset by lower public company
expenses in the current year period due to favourable foreign exchange compared to prior year period.
SUMMARY OF QUARTERLY FINANCIAL RESULTS
| | |
Jun. 30
2022 | |
Mar. 31
2022 | |
Dec. 31
2021 | |
Sep. 30
2021 | |
Jun. 30
2021 | |
Mar. 31
2021 | |
Dec. 31
2020 | |
Sept. 30
2020 |
| | |
$ | |
$ | |
$ | |
$ | |
$ | |
$ | |
$ | |
$ |
| Revenue | |
|
- |
| |
|
- |
| |
|
- |
| |
|
- |
| |
|
- |
| |
|
- |
| |
|
- |
| |
|
- |
|
| General and administration | |
| 1,919 | | |
| 1,936 | | |
| 1,990 | | |
| 1,964 | | |
| 1,867 | | |
| 2,009 | | |
| 2,093 | | |
| 1,691 | |
| Research and development | |
| 2,411 | | |
| 1,191 | | |
| 2,907 | | |
| 6,269 | | |
| 4,349 | | |
| 3,701 | | |
| 3,180 | | |
| 2,176 | |
| Net loss | |
| (4,155 | ) | |
| (3,206 | ) | |
| (4,807 | ) | |
| (8,178 | ) | |
| (6,386 | ) | |
| (5,813 | ) | |
| (5,338 | ) | |
| (3,786 | ) |
| Basic and diluted loss per share | |
| (0.07 | ) | |
| (0.06 | ) | |
| (0.09 | ) | |
| (0.15 | ) | |
| (0.12 | ) | |
| (0.11 | ) | |
| (0.11 | ) | |
| (0.08 | ) |
| Total assets | |
| 20,140 | | |
| 23,456 | | |
| 26,107 | | |
| 30,093 | | |
| 37,336 | | |
| 42,252 | | |
| 36,323 | | |
| 37,640 | |
| Total liabilities | |
| 2,147 | | |
| 2,621 | | |
| 2,351 | | |
| 5,431 | | |
| 4,958 | | |
| 4,107 | | |
| 2,216 | | |
| 1,656 | |
R&D expenses fluctuate quarter over quarter based on activities ongoing
during that period. During the quarter ended June 30, 2021 there was a $1.8 million reimbursement received from CPRIT which offset increased
R&D expenses, primarily due to manufacturing and pre-clinical costs associated with MDNA11. The increase in expenditures from the
quarter ended December 31, 2020 onwards, is primarily related to activities associated with the MDNA11 program and establishment of the
BiSKITsTM program. One-time higher CMC costs, associated with the scale-up GLP and GMP manufacturing of MDNA11 was completed
in the quarter ended September 30, 2021, resulting in a decrease in R&D expenses from the quarter ended December 31, 2021 onwards.
Refundable tax credits of $0.7million contributed to decreased R&D expenses during the quarter ended March 31, 2022.
G&A expenses began to increase in the quarter ended December 31,
2020, due to increased in directors and officers liability insurance premiums. Directors and officers liability insurance premiums are
amortized for 2 months in the quarter ended September 30, 2020, with 3 months each subsequent quarter.
LIQUIDITY AND CAPITAL RESOURCES
Since inception, the Company has devoted its resources to funding R&D
programs, including securing intellectual property rights and licenses, conducting discovery research, manufacturing drug supplies, initiating
preclinical and clinical studies, submitting regulatory dossiers and providing administrative support to R&D activities, which has
resulted in an accumulated deficit of $75.1 million as of June 30, 2022. With current revenues only consisting of interest earned on excess
cash, cash equivalents and marketable securities, losses are expected to continue while the Company’s R&D programs are advanced.
We currently do not earn any revenues from our product candidates and
are therefore considered to be in the development stage. As required, the Company will continue to finance its operations through the
sale of equity or pursue non-dilutive funding sources available to the Company in the future. The continuation of our research and development
activities for MDNA55, MDNA11 and the BiSKITsTM platform and the commercialization of MDNA55 is dependent upon our ability
to successfully finance and complete our research and development programs through a combination of equity financing and revenues from
strategic partners. We have no current sources of revenues from strategic partners.
The accompanying interim condensed consolidated financial statements
have been prepared on a going concern basis in accordance with International Financial Reporting Standards (IFRS) as issued by the International
Accounting Standards Board (IASB). The going concern basis contemplates the realization of assets and the settlement of liabilities in
the normal course of business as they come due for the foreseeable future. Management has forecasted that the Company’s current
level of cash is expected to be able to fund operations into Q1 of fiscal 2024. Subsequent to quarter end, the Company completed a financing
which raised an additional US$20 million. This additional cash is expected to fund operations into Q1 of calendar 2024. For
further details, see Note 10 in interim condensed consolidated financial statements.
CASH POSITION
At June 30, 2022, we had a cash, cash equivalents and marketable securities
balance of $19.3 million, compared to $20.5 million at March 31, 2022. We invest cash in excess of current operational requirements in
highly rated and liquid instruments. Working capital at June 30, 2022 was $17.9 million (March 31, 2022 - $20.8 million).
On December 30, 2020, we announced that
we entered into the ATM Agreement with SVB Leerink acting as sales agent for our ATM offering of up to US$25.0 million. We plan to use
the net proceeds of the ATM Facility for general corporate purposes including, but not limited to working capital expenditures, research
and development expenditures, and clinical trial expenditures. As of June 30, 2022, a total of 3,803,613 common shares have been sold
under the ATM Facility for total gross proceeds of $12.0 million (US$9.7 million). As of June 30, 2022, approximately $19.1 million
(US$15.3 million) remained available under the ATM Facility.
We do not expect to generate positive cash flow from operations for
the foreseeable future due to additional R&D expenses, including expenses related to drug discovery, preclinical testing, clinical
trials, chemistry, manufacturing and controls and operating expenses associated with supporting these activities. It is expected that
negative cash flow from operations will continue until such time, if ever, that we receive marketing authorization to commercialize any
of our product candidates under development and/or royalty or milestone revenue from any such products should they exceed our expenses.
CONTRACTUAL OBLIGATIONS
CPRIT Assistance
In February 2015, the Company received notice that it had been awarded
a grant by the CPRIT whereby the Company was eligible to receive up to US$14.1 million on eligible expenditures over a three-year period
related to the development of the Company’s phase 2b clinical program for MDNA55. As of March 31, 2022, all of the US$14.1 million
had been received and the grant with CPRIT is complete.
Under the terms of the grant, the Company is required to pay a royalty
to CPRIT, comprised of 3-5% of revenues on net sales of MDNA55 until aggregate royalty payments equal 400% of the grant funds received
at which time the ongoing royalty will be 0.5% of revenues. At this time the royalty is not probable and therefore no liability has been
recorded. In addition, the Company must maintain a presence in Texas for three years following completion of the grant.
Refundable tax credits
In June 2022, the company received $0.7 million through our Australian
R&D incentive program relating to the year ended March 31, 2022. The amount receivable was recorded as a reduction in research and
development expenses in the year ended March 31 2022.
Intellectual Property
The Company has entered into various license agreements with respect
to accessing patented technology. In order to maintain these agreements, the Company is obligated to pay certain costs based on timing
or certain milestones within the agreements, the timing of which is uncertain. These costs include ongoing license fees, patent prosecution
and maintenance costs, royalty and other milestone payments. As at June 30, 2022, the Company is obligated to pay the following:
| · | Given the current development plans and expected timelines of the Company it is assumed that project milestones
of US$0.3 million will be due in the next five years. |
| · | Project milestone payments, assuming continued success in the development programs, of uncertain timing
totaling US$2.0 million and an additional US$2.0 million in sales milestones. |
As part of these license agreements, the Company has committed to make
certain royalty payments based on net sales to the NIH and Stanford.
Future commitments
As of June 30, 2022, we have the following obligations to make future
payments, representing contracts and other commitments that are known and committed:
| | |
Payments Due by Period |
| Contractual obligations | |
Less than 1
year | |
1-3 years | |
3-5 years | |
Total |
| Patent licensing costs, minimum annual royalties per license agreements | |
$193 | |
$ | 1,173 | | |
$ | 296 | | |
$ | 1,662 | |
| | |
| |
| | | |
| | | |
| | |
The Company cannot reasonably estimate future royalties which may be due
upon the marketing authorization of MDNA55 or MDNA11.
As at the date of this report, we had obligations to make future
payments, representing significant research and development and manufacturing contracts and other commitments that are known and committed
in the amount of approximately $10.7 million, of which $8.6 million has been paid or accrued at June 30, 2022. Most of these agreements
are cancellable by the Company with notice. These commitments include agreements for clinical contract research organizations, manufacturing
and preclinical studies.
OFF-BALANCE SHEET ARRANGEMENTS
The Company has no material undisclosed off-balance sheet arrangements
that have, or are reasonably likely to have, a current or future effect on our results of operations, financial condition, revenues or
expenses, liquidity, capital expenditures or capital resources that is material to investors.
TRANSACTIONS WITH RELATED PARTIES
Key management personnel, which consists of the Company’s officers
(Dr. Fahar Merchant, President and Chief Executive Officer, Ms. Elizabeth Williams, Chief Financial Officer, Ms. Rosemina Merchant, Chief
Development Officer, Dr. Mann Muhsin, former Chief Medical Officer, and Dr. Kevin Moulder, former Chief Scientific Officer) and directors,
received the following compensation for the following periods:
| | |
|
Three months
ended June 30,
2022 |
| |
|
Three months
ended June 30,
2021 |
|
| | |
| $ | | |
| $ | |
| Salaries and wages | |
| 253 | | |
| 391 | |
| Board fees | |
| 76 | | |
| 72 | |
| Stock option expense | |
| 342 | | |
| 207 | |
| | |
| 671 | | |
| 670 | |
As at June 30, 2022, the Company had trade and other payables in the
normal course of business, owing to directors and officers of $0.1 million (2021: $0.2 million) related to accrued bonuses, board fees
and accrued vacation.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The significant accounting policies of the Company are described in note 2
of the Annual Financial Statements and available on SEDAR at www.sedar.com and included in the Annual Report on Form 20-F filed on EDGAR
at www.sec.gov.
Estimates and assumptions are continually evaluated and are based on
historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
The determination of estimates requires the exercise of judgement based on various assumptions and other factors such as historical experience
and current and expected economic conditions. Actual results could differ from those estimates. Critical judgements in applying the Company’s
accounting policies are detailed in the Annual Financial Statements, filed on SEDAR at www.sedar.com and included in the Annual Report
on Form 20-F filed on EDGAR at www.sec.gov.
FINANCIAL INSTRUMENTS
Financial instruments are defined as a contractual right or obligation
to receive or deliver cash on another financial asset. The Company recognizes financial instruments based on their classification. Depending
on the financial instrument’s classification, changes in subsequent measurements are recognized in net loss or other comprehensive
loss.
A description of the financial instruments, their fair value and risk
management is included in notes 2, 5 and 6 of the Annual Financial Statements, filed on SEDAR at www.sedar.com and included in the Annual
Report on Form 20-F filed on EDGAR at www.sec.gov/edgar.
2020 Public Offering and USE OF
PROCEEDS
The following table provides an update on the anticipated use of proceeds
raised in the 2020 Public Offering along with amounts actually expended. Following completion of the 2020 Public Offering, Medicenna selected
MDNA11 as its lead IL-2 candidate over MDNA19 to progress to the clinic and, as such, proceeds from the 2020 Public Offering, which were
initially allocated to the development of MDNA19, have been re-directed to the development of MDNA11 in the same proportions. As of June
30, 2022, the following expenditures have been incurred (in thousands of Canadian dollars):
| Item |
Amount to Spend |
Spent to Date |
Adjustments |
Remaining to Spend |
| Preclinical development |
$ 3,300 |
$ 3,300 |
- |
- |
| Manufacturing of clinical batch |
$ 4,400 |
$ 4,400 |
- |
- |
| Clinical development |
$ 13,150 |
$ 5,186 |
- |
$ 7,964 |
| General corporate and working capital purposes |
$ 11,350 |
$ 11,350 |
- |
- |
| Total |
$ 32,200 |
$ 24,236 |
$ - |
$ 7,964 |
ATM Facility
On December 30, 2020, the Company entered into the ATM Agreement with
SVB Leerink acting as sales agent, pursuant to which the Company may, from time to time sell, through ATM offerings, on the Nasdaq such
number of common shares as would have an aggregate offering price of up to US$25.0 million. During the three month period ended June 30,
2022, the Company has issued 656,656 common shares, raising total gross proceeds of $1.0 million under the ATM Facility. As at June 30,
2022, there were approximately US$15.3 million ($19.1 million) available to use on the ATM Facility.
RISKS AND UNCERTAINTIES
The Company is an immunotherapy company that operates in a highly competitive
industry that is dependent on a number of factors that include the Company’s capacity to raise additional funding on reasonable
terms when necessary, secure partnerships for the development of its product candidates, obtain necessary regulatory approvals and achieve
market acceptance, face disruption in availability of key components for ongoing clinical studies, obtain positive results from pre-clinical
and clinical studies, successfully develop existing and new products, hire and retain skilled staff and key personnel, rely on third party
providers, protect its intellectual property, and face litigation risk in connection thereof. An investment in the Common Shares is subject
to a number of risks and uncertainties, including the risks related to the Company being a foreign private issuer.
In addition, the Company may, from time to time, announce or publish preliminary
or interim data from its clinical trials. Preliminary and interim data remains subject to audit and verification procedures that may
result in the final data being materially different from the preliminary or interim data. Preliminary and interim results of a clinical
trial are not necessarily predictive of final results. There can be no assurance that favorable interim or preliminary data will result
in favorable final data. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially
change as patient enrollment continues, patient data are further examined and reviewed, more patient data become available, and the Company
prepares and issues its final clinical study report. As a result, preliminary and interim data should be viewed with caution until the
final, complete data are available. Material adverse changes in the final data compared to the preliminary or interim data could significantly
harm the Company’s business, prospects, financial condition and results of operations.
An investor should carefully consider these risks, as well as the risks described
in the Company’s Annual Information Form and the Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission,
as well as the other information filed with the securities regulators before investing in the Common Shares. If any of such described
risks occur, or if others occur, the Company’s business, financial condition and the results of operations could be seriously harmed
and investors could lose all or part of their investment.
There are important risks which management believes could impact the
Company’s business. For information on risks and uncertainties, please also refer to the “Risk Factors” section
of the Company’s most recent Annual Information Form filed on SEDAR at www.sedar.com and
included in the Annual Report on Form 20-F filed on EDGAR at www.sec.gov/edgar.
DISCLOSURE CONTROLS AND INTERNAL CONTROL OVER FINANCIAL REPORTING
The Company has implemented a system of internal controls that it believes
adequately protects the assets of the Company and is appropriate for the nature of its business and the size of its operations. The internal
control system was designed to provide reasonable assurance that all transactions are accurately recorded, that transactions are recorded
as necessary to permit preparation of financial statements in accordance with IFRS, and that our assets are safeguarded.
These internal controls include disclosure controls and procedures designed
to ensure that information required to be disclosed by the Company is accumulated and communicated as appropriate to allow timely decisions
regarding required disclosure.
Internal control over financial reporting means a process designed by
or under the supervision of the Chief Executive Officer and the Chief Financial Officer, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS as issued
by the IASB.
The internal controls are not expected to prevent and detect all misstatements
due to error or fraud. There were no changes in our internal control over financial reporting that occurred during the three-month period
ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial
reporting.
As of June 30, 2022, the Company’s management has assessed the
effectiveness of our internal control over financial reporting and disclosure controls and procedures using the Committee of Sponsoring
Organizations of the Treadway Commission’s 2013 framework. Based on their evaluation, the Chief Executive Officer and the Chief
Financial Officer have concluded that these controls and procedures are effective.
OTHER MD&A REQUIREMENTS
Outstanding Share Data
As at the date of this report, the Company has the following securities
outstanding:
| |
Number |
| Common shares |
69,637,469 |
| Warrants |
16,297,876 |
| Stock options |
5,580,353 |
| Total |
91,515,698 |
For a detailed summary of the outstanding securities convertible into,
exercisable or exchangeable for voting or equity securities of Medicenna as at March 31, 2022, refer to notes 9, 10, and 11 of the Annual
Financial Statements of the Company.
Additional information relating to the Company, including the Company’s
Annual Information Form and the Annual Report on Form 20-F, is available under the Company’s profile on SEDAR at www.sedar.com and
EDGAR at www.sec.gov, respectively.
21